Background: Menopause causes a variety of symptoms such as hot flashes and night
sweats. While menopausal hormonal therapy has been used for managing postmenopausal …

This systematic review and meta-analysis investigated the efficacy and safety of fezolinetant
for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with …

Background One in eight women will be diagnosed with breast cancer. At the time of
diagnosis, 75% of patients are postmenopausal. Many will receive anti-hormone therapy …

Abstract Background & Objective Vasomotor symptoms (VMS) are the most common
symptoms during menopause including hot flushes and night sweats. They are highly …

Neuropeptides, including tachykinins, CGRP, and somatostatin, are localized in a
peptidergic subgroup of nociceptive primary afferent neurons. Tachykinins and CGRP are …

Abstract Objective The phase II STARLIGHT study was conducted to investigate the
efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future …

NK 1 receptor antagonists are used clinically for the prevention of nausea and vomiting
caused by chemotherapy and for postoperative nausea and vomiting. They represent an …

Updates in nonhormonal therapy for perimenopausal and menopausal symptoms Page 1
GCO 370207 CURRENT OPINION Updates in nonhormonal therapy for perimenopausal …

We thank Dr. Douxfils and team for their e-letter (1) in response to the PEER team's article
Top studies of 2023 relevant to primary care.(2) The Top Studies of 2023 article is limited in …

Etwa 1½ Stunden nach oraler Einnahme von Fezolinetant werden maximale Plasmaspiegel
erreicht. Die biologische Verfügbarkeit soll über 90% betragen. Das Medikament wird …